内幕交易！688366，实控人被罚

Core Viewpoint - The actual controller of Haohai Biological Technology, Jiang Wei, was penalized approximately 19.34 million yuan for insider trading and related activities, which the company claims will not significantly impact its operations or finances [2][4][6]. Group 1: Penalty Details - Jiang Wei was fined 1,463 million yuan and had 471 million yuan of illegal gains confiscated by the China Securities Regulatory Commission (CSRC) [4][6]. - The penalty is directed at Jiang Wei personally and is stated to be unrelated to the company's operations [6][7]. Group 2: Shareholding Structure - As of the end of the third quarter, Jiang Wei is the largest shareholder of Haohai Biological, holding 66.528 million shares, which accounts for 28.6% of the total shares [7][8]. - The top ten shareholders collectively hold 79.3% of the total shares, with Jiang Wei and You Jie being the main controllers of the company [8]. Group 3: Business Developments - Haohai Biological plans to invest 38.35 million yuan to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd., which specializes in the research, production, and sales of biological amniotic membranes [11][12]. - The investment aims to enhance the company's product portfolio and expand its business coverage in the ophthalmology and orthopedics sectors [11]. Group 4: Financial Performance of Target Company - Ruiji Biological reported a projected net profit of -12.74 million yuan for 2024, with a loss of 11.93 million yuan in the first three quarters of the current year [12][13]. - The transaction does not include performance commitments or guarantees, indicating potential risks for Haohai Biological if Ruiji's performance declines [13]. Group 5: Market Position - As of December 23, Haohai Biological's stock price was 44.25 yuan per share, with a total market capitalization of 10.292 billion yuan [14].